AbbVie said on Monday its newer arthritis drug Rinvoq showed superiority over the company's previous bestseller Humira, ...

The updated indication for the JAK inhibitor allows use in patients with moderately to severely active ulcerative colitis and ...

I rate AbbVie stock as a Strong Buy, based on its FDA approval of Rinvoq. Read the latest analysis on the stock here.

The US Food and Drug Administration (FDA) has approved AbbVie’s supplemental new drug application, updating the indication ...

ABBV leans on booming Skyrizi and Rinvoq-driven sales to sustain growth and counter Humira's decline as Q3 results approach.

The Food and Drug Administration (FDA) has approved updated indications for Rinvoq® (upadacitinib) in the treatment of adults with moderately to severely active ulcerative colitis (UC) or Crohn ...

AbbVie has received the U.S. Food and Drug Administration (FDA) approval for a supplemental new drug application (sNDA) that ...

AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) approval of a supplemental new drug application (sNDA) that updates the indication statement for RINVOQ® (upadacitinib) ...

US FDA approves updated indication statement for AbbVie’s Rinvoq for the treatment of inflammatory bowel disease: North Chicago, Illinois Wednesday, October 15, 2025, 12:00 Hrs ...

The FDA updated the indication of the JAK inhibitor upadacitinib (Rinvoq) in inflammatory bowel disease (IBD) to account for ...

The Food & Drug Administration granted AbbVie expanded approval for its Rinvoq drug intended to treat moderately to severely active ulcerative colitis and moderately to severely active Crohn's disease ...

AbbVie (ABBV) on Monday said that the U.S. Food and Drug Administration has approved an update to the indication statement ...